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spectral photon fluence and of the fluence contributions by 
scattered and primary photons were evaluated. The effects 
of phantom material composition, especially of the organic 
polymer density and of the amount of inorganic additives, 
were also studied in terms of the resulting linear attenuation 
coefficient μ. 
 
Results: Significant differences were seen in the degree of 
water equivalence between the phantom materials covered 
by this study. While RW1, RW3, Solid Water, HE Solid Water, 
Virtual Water, Plastic Water DT and Plastic Water LR 
phantoms show dose deviations of less than 1.4% in all 
phantom sizes, Original Plastic Water (2015), Plastic Water 
(1995), Blue Water, polyethylene and polystyrene produce 
deviations up to 8.1 %. The role of PMMA is unique, showing 
deviations up to 4.3 % in phantoms with radii below 10 cm, 
but below 1 % in larger phantoms. Scattered photons with 
energies reaching down into the 25 keV region dominate the 
photon fluence at source distances exceeding 3.5 cm. The 
degree of water equivalence of a phantom material is 
correlated with the equivalence of its linear attenuation 
coefficient µ with that of water over a large energy range. 
 
Conclusion: The key feature of a suitable water substitute 
material is the agreement of its linear attenuation coefficient 
µ with that of water over a large range of photon energies. 
This precondition provides water equivalence with regard to 
the attenuation of the primary photons, the release of low-
energy photons by Compton scattering and their attenuation 
by a combination of the photoelectric and Compton effects. 
The instrument to achieve this goal is a balanced content of 
inorganic additives in a plastic phantom material. 
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Purpose or Objective: Brachytherapy (BT) can be 
administrated by low (E < 50 keV), intermediate (50 keV < E < 
200 keV) or high (E > 200 keV) energy sources. For the lower 
energy sources, the photoelectric effect dominates the 
energy deposition and the dose distribution decreases rapidly 
as the inverse of the distance from the source. For the 
intermediate and high energy sources, Compton scattering is 
the dominant photon interaction. The attenuation in tissue is 
compensated by the photon scatter build-up of the dose. 
Radiation sources used in high dose rate (HDR) BT have 
conventionally provided near-isotropic or radially symmetric 
dose distributions, delivering very high doses to tumours but 
often with poor tumour dose conformity due to the 
asymmetric shape of the tumours. Rotating shield 
brachytherapy (RSBT), is a HDR BT technique delivered 
through shielded, rotating catheters, providing 
unprecedented control over radiation dose distributions. 
However, its application in clinical practice has been limited 
due to lack of an appropriate radiation source. In this work, 
gadolinium-153 (153Gd) was produced as source isotope for 
use in RSBT. 
 
Material and Methods: A sample of isotopically enriched 
152Gd with precisely known mass was irradiated in the 
reactor core at McMaster Nuclear Reactor (MNR) site. The 
radioactive 153Gd formed was counted on a high purity 
germanium detector to determine the effective neutron 
capture cross-section of 152Gd. A sample of natural 
gadolinium oxide powder was heated at 1000 °C in a muffle 
furnace to make it more compact. Radioactive gadolinium 
with known activity was loaded on a series of solid substrates 
and the remaining activity in the substrate was measured to 
determine the loading capacity for each sorbent. The 
maximum specific activity of 153Gd produced from enriched 
152Gd at MNR was predicted by modelling studies. Finally, a 
prototype of the 153Gd source was encapsulated in a 
titanium casing. 
 
Results: The effective thermal neutron capture cross-section 
was determined to be 500 b. The maximum density of 
gadolinium oxide after heating was 2.2 g/cm3, significantly 
lower than the literature value of 7.4 g/cm3, which refers to 
the metal oxide state. Dowex 50x6 resin was found to have 
the greatest loading capacity for gadolinium at 219.6 mg/g 
sorbent. 153Gd could be produced with a maximum 
achievable specific activity of 150 Ci/g of 152Gd at MNR after 
3 months of continuous irradiation. 153Gd emits 40-100 keV 
photons with a dose distribution similar to that of iridium-192 
(192Ir) due to its intermediate energy, but with much lower 
shielding requirements (TVL of 3.7 mm in platinum). 
 
Conclusion: We have developed a means of immobilizing and 
encapsulating a 153Gd source for potential use in 
brachytherapy. A 153Gd BT source can be used in 
combination with a shielding system to deliver RSBT. 
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Purpose or Objective: In this study we evaluated the 
Advance Collapsed cone Engine (ACE) algorithm for clinical 
application to Brachytherapy. To this purpose, we followed 3 
main objectives: 1) commission the ACE algorithm, 2) 
Validate this algorithm as compared to measurement and 
Monte Carlo simulation and 3) quantify the dosimetric 
differences observed as compared to TG43 for 3 common 
clinical indications. 
 
Material and Methods: We followed the AAPM TG186 
guidelines for MBDCA commissioning. This task group 
recommends to commission the dose calculation algorithm by 
1) performing calculation in simple geometry 2) verifying 
dose calculation with hand calculation 3) comparing dose 
calculation results in complex geometries with a MC based 
algorithm. We developped a dedicated 6 source positions 
phantom allowing homogeneous dose distribution at the point 
of measurement in order to perform dose calculation and 
measurements in air and liquid water with or without 
heterogeneities introduced (Air, PMMA, Lead, Cortical Bone). 
Based on this phantom, we performed measurement using 3 
different detectors, a A1SL detector, a Farmer chamber and 
TLD measurements. Measurements have been compared to 
dose calculated using ACE, TG43 and validated MC (MCNPX 
and Fluka). Finally ACE algorithm has been used on 19 
Gynecologic, 11 Lips and 21 Penis patients where clinical 
common indicators (V250%, V100%, D2cc, V100%CTV ...) have 
been compared to TG43 and MC calculated dose distribution. 
 
Results: Simple geometries with a uniform phantom have 
shown agreement within 0.3% between ACE and TG43 for 
both point and line sources. Using dedicated phantom, TG43 
vs ACE in air and in water measurements with lead 
heterogeneity showed up to 95% difference and 86% 
respectively. ACE vs measurements showed an agreement 
within 3% in air and 0.3% in liquid water using several 
heterogeneity media (Table1).  
 
